![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Halozyme Therapeutics
HALO
Precision Drilling
PDS
Collegium Pharmaceutical
COLL
Hutchmed (China)
HCM
Ermenegildo Zegna NV
ZGN
US Stock MarketDetailed Quotes
BEAM Beam Therapeutics
- 28.730
- +0.840+3.01%
Trading Feb 27 12:06 ET
2.40BMarket Cap-6.27P/E (TTM)
29.214High28.130Low379.44KVolume28.140Open27.890Pre Close10.92MTurnover0.55%Turnover RatioLossP/E (Static)83.69MShares40.65052wk High3.28P/B1.97BFloat Cap20.84052wk Low--Dividend TTM68.57MShs Float138.522Historical High--Div YieldTTM3.89%Amplitude13.000Historical Low28.770Avg Price1Lot Size
Beam Therapeutics Stock Forum
Sign in to post a comment
$Hims & Hers Health (HIMS.US)$ , an online health and wellness platform, has seen its stock soar over 78% since February, with a year-to-date surge exceeding 174%. This outpaces the projected full-year gain of 171% for 2024.
What's Fueling HIMS' Rally?
HIMS surged 17.5% on Wednesday following the announcement of an acquisition, reaching an intraday high of nearly 25% and hitting a record $72.
Hims & Hers disclosed it acquired Sigmund NJ LLC, also known as Trybe La...
What's Fueling HIMS' Rally?
HIMS surged 17.5% on Wednesday following the announcement of an acquisition, reaching an intraday high of nearly 25% and hitting a record $72.
Hims & Hers disclosed it acquired Sigmund NJ LLC, also known as Trybe La...
30
2
43
The attention of AI Medteck stocks are rapidly increasing.
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...
113
13
279
US Congress member Nancy Pelosi and Ark Invest's Cathie Wood both bet big on an AI stock recently.
The stock in question is $Tempus AI (TEM.US)$, a company that uses data and artificial intelligence (AI) to create precision medicine services. ARK Invest, a prominent advocate for innovative technologies, first showed interest on December 6, when it purchased shares in this healthcare technology firm. Since that initial investment, Tempus AI h...
The stock in question is $Tempus AI (TEM.US)$, a company that uses data and artificial intelligence (AI) to create precision medicine services. ARK Invest, a prominent advocate for innovative technologies, first showed interest on December 6, when it purchased shares in this healthcare technology firm. Since that initial investment, Tempus AI h...
45
7
154
$Beam Therapeutics (BEAM.US)$
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics (NASDAQ: BEAM) presented new data for its ESCAPE conditioning platform at the ASH Annual Meeting. The data demonstrated successful proof-of-concept in non-human primates (NHPs) for a non-genotoxic conditionin...
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics (NASDAQ: BEAM) presented new data for its ESCAPE conditioning platform at the ASH Annual Meeting. The data demonstrated successful proof-of-concept in non-human primates (NHPs) for a non-genotoxic conditionin...
1
As the U.S. presidential election approaches in just two months, focus intensifies on the crucial debate between Vice President Kamala Harris and former President Donald Trump, scheduled for 9 p.m. ET on Tuesday, September 10. For investors strategizing around the "Trump trade" or the "Harris trade," the market's forward-looking reaction to their governing policies is critical. The election outcome will shape expectations of their administra...
+1
45
11
38
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
9
2
$Beam Therapeutics (BEAM.US)$ Will double to 90 dollars 💸 💵 💲
1
2
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
7
1
Beam Therapeutics' CEO, John Evans showed confidence in Ms. Shaw's ability to turn scientific innovations into commercial treatments. Shaw recognizes Beam's groundbreaking work in genetic medicine and gene editing, predicting major clinical milestones ahead thanks to the company's comprehensive platform and capabilities.
No comment yet
sooogod : nbis.
GOGOY : Tem will be the next